FDA Authorization of OTC and Home-Use Diagnostic Tests: Pathways, Precedents, and Evidence

FDA authorization of OTC and home-use diagnostic tests: pathways, precedents, and the evidence that clears them

Over-the-counter (OTC) and home-use in vitro diagnostic (IVD) tests reach the U.S. market through the same premarket pathways as any other device, the 510(k) and the De Novo, but they carry a distinct evidence burden. Because the operator is a lay person and the setting is uncontrolled, FDA shifts the center of gravity of the submission from analytical performance alone to a combined package of lay-user clinical performance, usability, and label comprehension. A parallel but separate question, CLIA complexity categorization, governs whether a professional point-of-care (POC) version of the same test can be run in a waived setting by untrained operators. This overview sets out how FDA has structured these decisions and the study designs that have supported clearance across respiratory, sexual-health, metabolic, and drugs-of-abuse tests.

Two distinct questions: market pathway and CLIA complexity

For OTC/home-use IVDs there are really two regulatory determinations in play, and they should not be conflated.

The first is the premarket pathway. Most OTC IVDs are cleared through the 510(k) route on the basis of substantial equivalence to a legally marketed predicate. When no suitable predicate exists for a novel home-use device type, FDA uses the De Novo process to establish a new Class II classification together with special controls that all future devices of that type must meet ¹⁰⁶⁹⁴.

The second is CLIA categorization. A test performed by professionals is categorized as high, moderate, or waived complexity. A CLIA waiver lets the test be run outside a certified laboratory, in physician offices and other POC settings, by operators with limited or no laboratory training. FDA guidance frames the waiver standard around two statutory findings: that the test is simple to use and that it poses an insignificant risk of an erroneous result, demonstrated by evidence that the test is accurate in the hands of the intended untrained user at representative use sites ¹⁴¹⁶²⁴. A home OTC test and a CLIA-waived POC test address different operators (a consumer versus an untrained professional user), but the evidence logic, accuracy in untrained hands under real-world conditions, is closely related.

The CLIA waiver evidence package

A manufacturer seeking a CLIA waiver for a previously cleared moderate-complexity test must show the test meets the statutory waiver criteria through studies conducted at intended-use sites, demonstrating accuracy and an insignificant risk of erroneous results, with labeling and instructions consistent with a device that is "simple" ¹⁴²²²⁴. FDA's recurring building blocks are:

Accuracy in the hands of the user. The revised guidance centers on comparable performance between a waived (untrained) user and a moderately complex laboratory user as the way to demonstrate accuracy ¹³¹⁶.
Comparison studies. Results from the candidate test in the hands of untrained operators are directly compared with an appropriate comparative method run by trained operators, in settings that replicate actual waived use as closely as possible, using representative sites, patients/samples, the intended sample matrix, and operators who resemble real waived users, with the test integrated into normal workflow ²⁴³⁵.
Reproducibility studies. FDA recommends at least three sites, the same number of untrained operators at each site, and building in the sources of variability that matter: sites, operators, days, runs, lots, and replicates. For certain qualitative tests, each untrained operator should run at least five positive and five negative samples by the comparative method ¹⁸.
Flex studies. Flex studies deliberately stress use-condition deviations to find where erroneous results appear. FDA's own example: for a step calling for three drops, a flex study can test one through six drops to identify when results fail, after which validation confirms that fail-safe mechanisms or alerts trigger when the procedure is done incorrectly ¹⁶. For POC tests, flex studies should identify the maximum deviation in conditions reasonably expected in the setting that still yields accurate results ²⁷. Some validation studies use blinded, randomized contrived specimens tested in real time under normal workflow, targeting at least 95% positive and negative agreement ²⁷.

The Dual 510(k) and CLIA Waiver by Application pathway

For a new test intended for waived use, FDA offers an optional Dual Submission that combines the 510(k) and the CLIA Waiver by Application into a single package, reducing overall review time versus sequential filings ²¹³⁶. A Dual Submission should follow a Pre-Submission, contain the same information as a complete 510(k) plus a complete waiver application, and remains subject to 510(k) Refuse to Accept policies ³⁴³⁶. The efficiency comes from study design: where a standalone 510(k) may rely on trained operators, the waiver requires untrained intended users in waived settings, so FDA recommends designing a single set of comparison and reproducibility studies performed by untrained operators that simultaneously supports substantial equivalence for the 510(k) and the simplicity/insignificant-risk findings for the waiver ¹⁵²⁴. A recent illustration is the VELO Respiratory Test (K251742), whose suitability for CLIA-waived testing was supported by clinical performance and usability studies in the hands of intended users, a cartridge-lot reproducibility study across three lots at negative, low-positive (2x LoD), and moderate-positive (4x LoD) levels, and flex studies varying workflow and operating-environment conditions ⁹⁹.

The OTC/home-use IVD evidence package

For a test placed directly in consumers' hands, FDA's guidance builds the submission around validating the entire use scenario in a home-like environment with intended lay users ¹². The core elements:

Lay-user clinical performance at representative sites. The clinical evaluation should be conducted at U.S. sites that mimic the home-use setting, enrolling users representative of the intended population across socioeconomic and educational backgrounds and a range of ages. Each participant should perform the entire workflow that applies to them: registration, specimen collection, testing, and results interpretation ¹.
Instructions written for lay users. The instructions for use should target no higher than a 7th grade reading level, run one to two pages, and include pictures and diagrams ¹².
Usability and user comprehension studies. FDA expects usability and user comprehension studies as part of the package, and for home-use workflows also reagent-stability and specimen-stability studies ¹².
Mitigating inadequate specimen collection. Acceptable approaches to the risk that a lay user collects a poor specimen include an internal control, video observation by a trained healthcare professional, or design features built into the collection device itself ¹².
Layered labeling studies for certain OTC products. For OTC products following the drug-facts-style model, FDA has recommended three usability studies: self-selection based on box labeling, correct and safe use after reading the instructions for use, and comprehension of the patient labeling (indications, contraindications, warnings, precautions). FDA advises small pretests of patient labeling, revision, then testing final draft labeling in a larger study, with retesting if labeling changes; pretesting methods include in-depth interviews, focus groups, self-administered questionnaires, usability testing, and readability testing ³⁶.

Precedents by category

Respiratory self-tests (SARS-CoV-2 and flu/COVID combinations)

The largest and most current body of OTC IVD precedent is the respiratory antigen self-test. These are 510(k) clearances built on a prospective lay-user clinical study, in which lay users self-collect an anterior nasal swab and self-test in a simulated home setting, with performance compared to an FDA-cleared molecular assay or RT-PCR comparator and reported as positive percent agreement (PPA) and negative percent agreement (NPA), typically paired with a usability/comprehension study. Representative clearances include:

Flowflex COVID-19 Antigen Home Test (K230828, ACON Laboratories): prospective lay-user study with anterior nasal swabs self-collected by users aged 14 or older (adult-collected for ages 2 to 13); PPA 89.8% and NPA 99.3% versus RT-PCR ⁶⁸.
OHC / CareSuperb COVID-19 Antigen Self Test (K241313, Osang; K241915, Access Bio): lay-user self-testing in a simulated home setting against an FDA-cleared molecular assay; PPA 97.2% and NPA 98.8% ⁵⁰.
GenBody COVID-19 Ag Home Test (K251916): clinical performance study with 1,096 evaluable subjects plus a 70-participant usability study in a simulated home-use environment; PPA 86.2% and NPA 100.0% ⁶¹.
Heal-Check Rapid COVID-19 Antigen Self-Test (K260095, Healgen): readability/usability study in lay users with critical/non-critical task completion in a simulated home environment, plus a clinical agreement study; PPA 86.7% and NPA 99.8% ⁶⁴.
Flu/COVID combinations: CareSuperb COVID-19/Flu A&B Antigen Combo Home Test (K251604, Access Bio) used a prospective lay-user study in a simulated home environment versus RT-PCR, reporting PPA 92.5% and NPA 99.6% for SARS-CoV-2 ¹⁴⁹⁵⁵; WELLlife Flu A&B Home Test (K251563, Wondfo) ran a multi-center prospective lay-user study of self-collected/self-tested anterior nasal swabs versus RT-PCR, enrolling 766 with 680 evaluable for Flu A/B ¹⁵¹. Healgen Rapid Check COVID-19/Flu A&B Antigen Test was authorized by De Novo (DEN240029), establishing a home-use lay-user classification for this combination test type ¹⁵².

Other cleared home antigen self-tests in this line include BinaxNOW COVID-19 Antigen Self Test (K243518, Abbott), iHealth COVID-19 Antigen Rapid Test (K233842), Flowflex Plus (K233373), and CorDx Tyfast (K240728) ⁴⁹⁸⁶⁵⁶³.

Home-collection and self-collection De Novos (sexual and cervical health)

Some of the most instructive recent precedents are De Novo classifications for home specimen collection and self-collection, where FDA wrote the special controls that define the device type.

Simple 2 Test (DEN200070, LetsGetChecked/Privapath): the foundational home-collection STI precedent. FDA established special controls requiring an appropriate OTC-indicated sample collection device (or one cleared in the submission with data showing lay users can collect specimens without healthcare-professional supervision), detailed intended-use labeling under 21 CFR 809.10, an intended use limited to lay-collectable specimen types backed by performance data, and design verification/validation covering test description, methodology, targets, controls, and the computational path to a result; labeling must state the kit requires shipment to a laboratory within a specified timeframe and direct users with recent exposure to seek care ¹⁰⁶¹⁴⁶. The classification was supported by remote usability/comprehension studies conducted from participants' homes by video conference: an initial vaginal-kit study with 85 female participants (after which instructions were aligned to the Hologic Aptima Multitest collection kit and FAQ sheets added), a second modified vaginal-kit study, and a final penile-urine-kit study with 32 male participants (using water to simulate urine to assess correct transfer volume). Each study assessed activation, packaging/shipping, comprehension of results and safety warnings, and laboratory evaluation for critical errors, demonstrating that lay users could collect samples at home without compromising the Aptima Combo 2 assay's performance ¹⁰⁴¹⁰¹¹⁴⁵¹⁰².
Teal Wand (DEN240045, Teal Health): a self-collection device for cervical cancer screening, classified with special controls requiring usability/user comprehension studies and clinical studies; the clinical study showed self-collected vaginal specimens obtained with the Teal Wand had high PPA versus clinician-collected cervical specimens (prescription use) ⁹⁴.
Visby Medical Women's Sexual Health Test (DEN240020) and First To Know Syphilis Test (DEN230090, NowDiagnostics): both classified as Class II with special controls covering labeling with limiting/performance statements and design verification/validation including analytical and clinical studies and risk-analysis strategies ¹⁰⁸¹⁰⁹.

Alongside these, BD's Onclarity Self-Collection Kit (K260184) was cleared via 510(k) using a prospective clinical study in a simulated home environment where lay users self-collected vaginal specimens compared with clinician-collected cervical specimens, with ambient-temperature transport and invalid-rate data supporting specimen handling ⁹⁵.

Metabolic self-monitoring: glucose, ketone, and A1c

Home blood glucose monitoring is the deepest OTC IVD precedent base, with a long line of 510(k) clearances for single-patient home-use systems (for example Rightest GM700S K190564, POGO K152493, StatStrip Xpress K170464, and many others) cleared on substantial equivalence to marketed OTC meters ¹⁵⁶¹⁵⁷¹⁶⁰. Where the record shows the supporting study, it follows the OTC pattern of lay-user accuracy against a reference method:

MTM301 Blood Glucose and Ketone Monitoring System (K202534, Apex BioTechnology): lay users independently completed setup and testing without assistance and reported ease of use on usability questionnaires; extreme low/high glucose accuracy was tested on 100 whole-blood samples versus the YSI 2300 analyzer, with 84% within +/-10% at low glucose and 96% within +/-10% at high glucose ¹⁵⁴.
On Call Sure GK system (K250085, ACON): a lay-user ketone evaluation with 101 participants self-collecting capillary fingerstick samples using only the labeling and system components, compared to a comparator method (for beta-ketone below 1.5 mmol/L, 97/97 within +/-0.30 mmol/L), with a supplemental altered-sample study at extreme concentrations ¹⁵⁵.

For hemoglobin A1c, the Home Access A1C Test (K141944) is a mail-in model rather than an on-device self-test: a lay-user-independent fingerstick capillary collection performed at home and shipped to a laboratory, cleared as OTC and not for diagnosis or screening ¹⁵³.

Drugs-of-abuse and other consumer screening tests

OTC home drugs-of-abuse urine tests form an established 510(k) category, cleared on comparison/accuracy studies against predicate devices or reference labs using clinical urine specimens, generally paired with mandatory GC/MS confirmatory-testing labeling rather than a formal lay-user usability study. The UCP Home Drug Screening devices (K091588, K122419) and the AllTest Home Rapid Test panels (K182738) illustrate the design, with 120 clinical urine samples per drug tested in the comparison study ¹¹³¹²¹. Numerous On Call, Instant-View, and IND home multi-drug products round out the category ¹²⁸¹²³¹²⁰.

In the pregnancy/fertility space, the LIA Pregnancy Test (K171136, Lia Diagnostics) was cleared using lay-user usability studies, a clinical performance study with self-performed testing by lay users, additional lay-user simulated mid-stream studies near the cutoff, and stability testing (result stability, shipping stability, and environmental factors) ⁹⁶.

What the precedents have in common

Across categories, the through-line is that FDA evaluates the whole use scenario, not just the assay. Three design principles recur:

Test the intended operator, not a proxy. Whether the operator is a consumer at home or an untrained professional in a waived setting, the pivotal performance data come from that operator performing the full workflow, self-collection through interpretation, under conditions that replicate real use ¹²⁴.
Pair clinical agreement with usability and comprehension. A strong PPA/NPA against a molecular comparator is necessary but not sufficient; FDA consistently expects usability, user comprehension, and (for OTC drug-facts-style products) self-selection and label-comprehension studies, plus reading-level and layout constraints on the instructions ¹²³.
Stress the failure modes and build in mitigations. Flex studies for waived tests and specimen-collection mitigations (internal controls, design features, video observation) for home tests are how sponsors show an insignificant risk of erroneous results despite untrained hands ¹⁶²⁷¹².

For a new device type without a predicate, the De Novo route additionally converts these expectations into binding special controls, as the Simple 2, Teal Wand, and syphilis/women's-health classifications show, so the same evidence that clears the first device also sets the bar for every follow-on 510(k) claiming that device as a predicate ¹⁰⁶⁹⁴¹⁰⁹.